FDA Commissioner Robert Califf (Tom Williams/CQ Roll Call via AP Images)

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

FDA Com­mis­sion­er Rob Califf told BIO CEO Rachel King on Wednes­day that it’s “im­pos­si­ble to ar­gue that the US is do­ing well in health,” high­light­ing high drug prices and mis­in­for­ma­tion as two key chal­lenges.

The com­mis­sion­er al­so took the op­por­tu­ni­ty to dis­cuss ac­cel­er­at­ed ap­proval re­forms, at­tri­tion at the agency and the In­fla­tion Re­duc­tion Act, which came in­to fo­cus ear­li­er this week when Mer­ck filed a law­suit call­ing parts of the drug pric­ing law a sham. In­dus­try crit­ics have ar­gued that the leg­is­la­tion will have a chill­ing ef­fect on in­no­va­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.